10 September 2020 - The purpose of this study was to evaluate the current state of health economic evaluations submitted by pharmaceutical companies to the Italian Medicines Agency as part of their pricing and reimbursement dossiers, and to explore potential future actions in order to enhance their quality.

All company dossiers submitted from October 2016 to December 2018 were reviewed to select those containing pharmacoeconomic studies. 

The general characteristics of health economic evaluations were described and their quality assessed based on a checklist adapted from Philips et al.

Read International Journal of Technology Assessment in Health Care article